Annals of Oncology Advance Access originally published online on August 17, 2005
Annals of Oncology 2005 16(11):1832-1840; doi:10.1093/annonc/mdi372
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 European Society for Medical Oncology
Molecular staging of the sentinel lymph node in melanoma patients: correlation with clinical outcome
Division of 1 Medical Oncology and 4 Plastic Surgery, University Hospital, Pisa; 2 Regional Center of Nuclear Medicine, 3 Pathology Unit, Department of Surgery and 5 Division of Dermatology, University of Pisa Medical School, Pisa, Italy
* Correspondence to: Dr A. Romanini, Division of Medical Oncology, ‘Santa Chiara’ University Hospital, Via Roma, 67, 56126 Pisa, Italy. Tel: +39-050-992645; Fax: +39-050-992070; E-mail: a.romanini{at}ao-pisa.toscana.it
Background: This study was designed to determine the debated prognostic significance of reverse transcriptase–polymerase chain reaction (RT–PCR) positivity in melanoma patients' sentinel lymph node (SLN) negative by conventional histopathology (PATH).
Patients and methods: Patients with primary stage I–II cutaneous melanoma underwent radioguided sentinel lymphadenectomy. Their SLNs were assessed for tyrosinase (Tyr) and melanoma antigens recognized by T-cells (MART-1) mRNA expression using RT–PCR, in parallel with hematoxylin and eosin staining and immunohistochemistry. Tyr and MART-1 expression in the SLNs were correlated with PATH assay results, standard prognostic factors, time to progression and overall survival.
Results: Twenty-three of the 124 patients (18.5%) had positive SLNs by both PATH and RT–PCR (PATH+/PCR+). Sixteen patients (13%) were negative by PATH and positive by RT–PCR (PATH–/PCR+). Eighty-five patients (68.5%) had SLNs that were negative by both PATH and RT–PCR (PATH–/PCR–). At a median follow-up of 30 months, recurrence rates among the three cohorts were statistically different (PATH+/PCR+, 60%; PATH–/PCR+, 31%; PATH–/PCR–, 9.4%). Seven of 23 (30%) and two of 16 (12.5%) patients died in the PATH+/PCR+ and PATH–/PCR+ SLN groups, respectively, whereas no patient died in the PATH–/PCR– SLN group.
Conclusions: RT–PCR is more sensitive than PATH to detect SLN metastases and it is a reliable predictor of disease relapse in stage I–II melanoma patients.
Key words: lymph node metastasis, melanoma, prognosis, RT–PCR, sentinel lymph node
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Manca, A. Romanini, D. Pellegrino, E. Borso, M. Rondini, C. Orlandini, V. Zucchi, F. Pasqualetti, and G. Mariani Optimal Detection of Sentinel Lymph Node Metastases by Intraoperative Radioactive Threshold and Molecular Analysis in Patients with Melanoma J. Nucl. Med., November 1, 2008; 49(11): 1769 - 1775. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mocellin, D. S.B. Hoon, P. Pilati, C. R. Rossi, and D. Nitti Sentinel Lymph Node Molecular Ultrastaging in Patients With Melanoma: A Systematic Review and Meta-Analysis of Prognosis J. Clin. Oncol., April 20, 2007; 25(12): 1588 - 1595. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Garrel, M. Dromard, V. Costes, E. Barbotte, F. Comte, Q. Gardiner, C. Cartier, M. Makeieff, L. Crampette, B. Guerrier, et al. The Diagnostic Accuracy of Reverse Transcription-PCR Quantification of Cytokeratin mRNA in the Detection of Sentinel Lymph Node Invasion in Oral and Oropharyngeal Squamous Cell Carcinoma: A Comparison with Immunohistochemistry Clin. Cancer Res., April 15, 2006; 12(8): 2498 - 2505. [Abstract] [Full Text] [PDF]
|
|